TMEPAI Confers Paclitaxel Resistance in Triple-Negative Breast Cancer Cells by Promoting AKT Phosphorylation and Its Downstream Cascade
TMEPAI appears to facilitate paclitaxel resistance in triple-negative breast cancer cells by promoting cell survival signaling, inhibiting apoptosis, enhancing drug efflux, and initiating epithelial-mesenchymal transition (EMT). Targeting TMEPAI may be a viable approach to overcoming resistance and improving treatment outcomes in triple-negative breast cancer cells.
Authors
- Melva Louisa (ORCID: https://orcid.org/0000-0002-9451-0380)
- Mitsuyasu Kato (ORCID: https://orcid.org/0000-0001-9905-2473)
- Yukihide Watanabe (ORCID: https://orcid.org/0000-0003-1014-2910)
- Bantari Wisynu Kusuma Wardhani
Institutions
- University of Tsukuba (JP)
- University of Indonesia (ID)
- National Research and Innovation Agency (ID)
Publication Details
- Journal
- Asian Pacific Journal of Cancer Prevention
- Published
- 2026-02-01
- DOI
- https://doi.org/10.31557/apjcp.2026.27.2.547
- Primary Topic
- Protein Kinase Regulation and GTPase Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitas Indonesia
- Fakultas Kedokteran, Universitas Indonesia